197 related articles for article (PubMed ID: 2542566)
1. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound.
Heinz BA; Rueckert RR; Shepard DA; Dutko FJ; McKinlay MA; Fancher M; Rossmann MG; Badger J; Smith TJ
J Virol; 1989 Jun; 63(6):2476-85. PubMed ID: 2542566
[TBL] [Abstract][Full Text] [Related]
2. Structural studies on human rhinovirus 14 drug-resistant compensation mutants.
Hadfield AT; Oliveira MA; Kim KH; Minor I; Kremer MJ; Heinz BA; Shepard D; Pevear DC; Rueckert RR; Rossmann MG
J Mol Biol; 1995 Oct; 253(1):61-73. PubMed ID: 7473717
[TBL] [Abstract][Full Text] [Related]
3. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14.
Shepard DA; Heinz BA; Rueckert RR
J Virol; 1993 Apr; 67(4):2245-54. PubMed ID: 8383239
[TBL] [Abstract][Full Text] [Related]
4. WIN 52035-dependent human rhinovirus 16: assembly deficiency caused by mutations near the canyon surface.
Wang W; Lee WM; Mosser AG; Rueckert RR
J Virol; 1998 Feb; 72(2):1210-8. PubMed ID: 9445020
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug.
Otto MJ; Fox MP; Fancher MJ; Kuhrt MF; Diana GD; McKinlay MA
Antimicrob Agents Chemother; 1985 Jun; 27(6):883-6. PubMed ID: 2992365
[TBL] [Abstract][Full Text] [Related]
6. Use of drug-resistance mutants to identify functional regions in picornavirus capsid proteins.
Mosser AG; Shepard DA; Rueckert RR
Arch Virol Suppl; 1994; 9():111-9. PubMed ID: 8032243
[TBL] [Abstract][Full Text] [Related]
7. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions.
Mosser AG; Sgro JY; Rueckert RR
J Virol; 1994 Dec; 68(12):8193-201. PubMed ID: 7966611
[TBL] [Abstract][Full Text] [Related]
8. Human rhinovirus 14 complexed with fragments of active antiviral compounds.
Bibler-Muckelbauer JK; Kremer MJ; Rossmann MG; Diana GD; Dutko FJ; Pevear DC; McKinlay MA
Virology; 1994 Jul; 202(1):360-9. PubMed ID: 8009848
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug.
Woods MG; Diana GD; Rogge MC; Otto MJ; Dutko FJ; McKinlay MA
Antimicrob Agents Chemother; 1989 Dec; 33(12):2069-74. PubMed ID: 2559655
[TBL] [Abstract][Full Text] [Related]
10. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug.
Fox MP; Otto MJ; McKinlay MA
Antimicrob Agents Chemother; 1986 Jul; 30(1):110-6. PubMed ID: 3019232
[TBL] [Abstract][Full Text] [Related]
11. VP4 protein from human rhinovirus 14 is released by pressure and locked in the capsid by the antiviral compound WIN.
Gonçalves RB; Mendes YS; Soares MR; Katpally U; Smith TJ; Silva JL; Oliveira AC
J Mol Biol; 2007 Feb; 366(1):295-306. PubMed ID: 17161425
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics simulations of human rhinovirus and an antiviral compound.
Speelman B; Brooks BR; Post CB
Biophys J; 2001 Jan; 80(1):121-9. PubMed ID: 11159387
[TBL] [Abstract][Full Text] [Related]
13. A novel benzonitrile analogue inhibits rhinovirus replication.
Lacroix C; Querol-Audí J; Roche M; Franco D; Froeyen M; Guerra P; Terme T; Vanelle P; Verdaguer N; Neyts J; Leyssen P
J Antimicrob Chemother; 2014 Oct; 69(10):2723-32. PubMed ID: 24948704
[TBL] [Abstract][Full Text] [Related]
14. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating.
Smith TJ; Kremer MJ; Luo M; Vriend G; Arnold E; Kamer G; Rossmann MG; McKinlay MA; Diana GD; Otto MJ
Science; 1986 Sep; 233(4770):1286-93. PubMed ID: 3018924
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional structures of drug-resistant mutants of human rhinovirus 14.
Badger J; Krishnaswamy S; Kremer MJ; Oliveira MA; Rossmann MG; Heinz BA; Rueckert RR; Dutko FJ; McKinlay MA
J Mol Biol; 1989 May; 207(1):163-74. PubMed ID: 2544734
[TBL] [Abstract][Full Text] [Related]
16. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.
Fox MP; McKinlay MA; Diana GD; Dutko FJ
Antimicrob Agents Chemother; 1991 Jun; 35(6):1040-7. PubMed ID: 1656851
[TBL] [Abstract][Full Text] [Related]
17. Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site.
Wald J; Pasin M; Richter M; Walther C; Mathai N; Kirchmair J; Makarov VA; Goessweiner-Mohr N; Marlovits TC; Zanella I; Real-Hohn A; Verdaguer N; Blaas D; Schmidtke M
Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19109-19115. PubMed ID: 31462495
[TBL] [Abstract][Full Text] [Related]
18. Structural analysis of antiviral agents that interact with the capsid of human rhinoviruses.
Badger J; Minor I; Oliveira MA; Smith TJ; Rossmann MG
Proteins; 1989; 6(1):1-19. PubMed ID: 2558377
[TBL] [Abstract][Full Text] [Related]
19. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors.
Pevear DC; Fancher MJ; Felock PJ; Rossmann MG; Miller MS; Diana G; Treasurywala AM; McKinlay MA; Dutko FJ
J Virol; 1989 May; 63(5):2002-7. PubMed ID: 2539499
[TBL] [Abstract][Full Text] [Related]
20. Pocket factors are unlikely to play a major role in the life cycle of human rhinovirus.
Katpally U; Smith TJ
J Virol; 2007 Jun; 81(12):6307-15. PubMed ID: 17428846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
